Introduction
============

Ovarian cancer is the most lethal gynecologic cancer, usually bearing a poor outcome ([@b1-ol-0-0-10818]). In 2019, a total of 22,530 new ovarian cancer cases and 13,980 ovarian cancer-associated mortalities were predicted to occur in the United States ([@b1-ol-0-0-10818]). Although aggressive surgery and combination chemotherapy have improved survival, the 5-year overall survival (OS) rate remains only 30% ([@b2-ol-0-0-10818]). Thus, identification of prognostic markers is of great need to allow improved risk prediction.

A metabolic hallmark of the majority of cancer cells is the shift from oxidative phosphorylation to aerobic glycolysis even with abundant oxygen, which is known as the Warburg effect ([@b3-ol-0-0-10818]). Since inhibiting the entry of pyruvate into the mitochondria leads to the redirection of glycolytic intermediates into the pentose phosphate pathway, which provides precursors for the synthesis of nucleotides and lipids, the Warburg effect contributes to the highly anabolic phenotype of cancer ([@b4-ol-0-0-10818]). Therefore, elevated expression of key enzymes that catalyze the pentose phosphate pathway has been observed in several types of cancer, including hepatocellular cancer ([@b5-ol-0-0-10818]) and colorectal carcinoma ([@b6-ol-0-0-10818]). The pentose phosphate pathway is responsible for the production of ribose-5-phosphate and NADPH ([@b7-ol-0-0-10818]). Ribose-5-phosphate is necessary for the synthesis of nucleic acids to meet the needs of rapidly proliferating tumor cells ([@b8-ol-0-0-10818]). The pentose phosphate pathway comprises two branches, oxidative and non-oxidative. The non-oxidative branch of the pentose phosphate pathway provides \>85% of ribose for nucleic acids synthesis of certain tumor cells, including pancreatic adenocarcinoma ([@b9-ol-0-0-10818]). The transketolase family genes encode thiamine-dependent enzymes, which are key enzymes in the non-oxidative part of the pentose phosphate pathway ([@b10-ol-0-0-10818]). The transketolase family comprises three human genes, transketolase (TKT) and TKT-like genes 1 and 2 (TKTL1 and TKTL2) ([@b11-ol-0-0-10818]).

Previous studies have revealed that the transketolase family genes serve important roles in the initiation, progression and cross-talk with other signaling pathways in cancer. Upregulated transketolase family genes have been identified in multiple types of cancer, including hepatocellular carcinoma ([@b5-ol-0-0-10818]), esophageal cancer ([@b12-ol-0-0-10818]), lung cancer ([@b13-ol-0-0-10818]), head and neck cancer ([@b14-ol-0-0-10818]), and colorectal carcinoma ([@b6-ol-0-0-10818]) and endometrial carcinoma ([@b15-ol-0-0-10818]). Overexpression of these genes is associated with poor outcome of patients with esophageal ([@b16-ol-0-0-10818]), lung ([@b17-ol-0-0-10818]), gastric ([@b18-ol-0-0-10818]), breast ([@b19-ol-0-0-10818]), colon and urothelial ([@b20-ol-0-0-10818]) cancer. Aberrant expression of transketolase family genes has also been observed in ovarian cancer ([@b21-ol-0-0-10818]). However, studies on the prognostic value of the transketolase family genes in ovarian cancer are limited ([@b22-ol-0-0-10818]). In addition, none of these studies have comprehensively assessed the prognostic effects of individual transketolase family components in ovarian cancer at the mRNA level. The aim of the present study was to determine the expression levels and prognostic significance of transketolase family genes in patients with ovarian carcinoma.

Materials and methods
=====================

### Datasets

Oncomine is an online collection of datasets with data mining platform ([@b23-ol-0-0-10818]). The expression of three transketolase family genes (TKT, TKTL1 and TKTL2) in normal ovarian tissues and ovarian cancer were analyzed by Oncomine. Bonome, Lu, Hendrix and the Cancer Genome Atlas cancer (TCGA) ovarian datasets were analyzed in the present study.

### Survival analysis

Kaplan-Meier plotter ([@b24-ol-0-0-10818]) is a widely used online database that integrates gene expression and clinical data of various types of cancer such as breast ([@b24-ol-0-0-10818]), lung ([@b25-ol-0-0-10818]) and ovarian ([@b26-ol-0-0-10818],[@b27-ol-0-0-10818]) cancer. In the present study, the progression-free survival (PFS) of 1,435 patients and OS of 1,656 patients with ovarian cancer were assessed using the Kaplan-Meier plotter database ([www.kmplot.com](www.kmplot.com)). The information about gene expression and survival of patients with ovarian cancer was collected from the Gene Expression Omnibus (GEO), Cancer Biomedical Informatics Grid (<http://cabig.cancer.gov/>) and TCGA cancer datasets ([@b28-ol-0-0-10818]). Clinical data, including stage, histology, grade, tumor protein p53 (TP53) mutation status and treatment, were also obtained. The association between transketolase gene mRNA levels and clinicopathological parameters was determined in patients with ovarian cancer with the corresponding clinical information. Transketolase family genes TKT, TKTL1 and TKTL2 were entered into the database to produce Kaplan-Meier survival plots. Patients were classified into 'low' and 'high'-expression groups according to the quantile expression of the proposed biomarker. Hazard ratio (HR) with 95% confidence intervals (CI) and log-rank P-value were calculated.

### Validation dataset

The GSE9891 dataset, which was part of the Kaplan-Meier plotter, was downloaded separately from GEO as a validation dataset ([@b29-ol-0-0-10818]). Expression data and clinic information of patients with ovarian cancer from GSE9891 were used to validate the prognostic values of transketolase family genes in ovarian cancer.

### Statistical analysis

Unpaired Student\'s-test was performed to compare the expression level of transketolase family genes between ovarian cancer and normal ovarian tissues from Oncomine. Results were presented in box plots. Kaplan-Meier curve was used to assess the association between expression of transketolase family genes and the survival rate in ovarian cancer. The log-rank test was used to compare the survival differences between the low and high-expression groups from the Kaplan-Meier plotter. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Transcription level of TKT in ovarian cancer compared with that in normal tissues

The transketolase family involves three human genes: TKT, TKTL1 and TKTL2. The differential expression of these three genes between normal ovarian tissue and ovarian cancer was analyzed using the Oncomine database. In the Bonome dataset, which comprised 185 ovarian cancer tissues and 10 normal ovarian tissues from patients with other gynecological diseases, the mRNA level of TKT in ovarian cancer tissue was higher compared with that in normal tissue ([Fig. 1A](#f1-ol-0-0-10818){ref-type="fig"}). In the TCGA dataset, which comprised 586 serous ovarian cancer samples and 8 adjacent normal ovarian tissues from patients with ovarian cancer, no difference in TKT expression was observed between serous ovarian cancer and normal ovarian tissue ([Table I](#tI-ol-0-0-10818){ref-type="table"}). Since other types of ovarian cancer were rare, TKT expression was systematically analyzed by combining the Lu and Hendrix datasets, in which ovarian cancer cases were classified by histological types. The results of the analysis demonstrated that TKT was upregulated in endometrioid, clear cell and mucinous ovarian cancer compared with its expression in normal ovarian tissue ([Table I](#tI-ol-0-0-10818){ref-type="table"}).

### Transcription level of TKTL1 in ovarian cancer compared with that in normal tissues

Compared with that in normal ovarian tissue, TKTL1 expression was increased by 1.398-fold in all ovarian cancer samples in the Bonome dataset ([Fig. 1B](#f1-ol-0-0-10818){ref-type="fig"}). According to the TCGA dataset, TKTL1 expression was increased by 2.384-fold in serous ovarian cancer compared with that in normal ovarian tissue (P\<0.001; [Table I](#tI-ol-0-0-10818){ref-type="table"}). However, no difference in TKTL1 expression was observed between endometrioid, clear cell or mucinous ovarian cancer and normal ovarian tissue ([Table I](#tI-ol-0-0-10818){ref-type="table"}).

### Transcription level of TKTL2 in ovarian cancer compared with that in normal tissues

No dataset compared TKTL2 expression between all ovarian cancer and normal ovarian tissues. Only the Lu dataset that separated ovarian cancer cases into different histological types was accessible in Oncomine; no significant differences in TKTL2 expression levels were observed between serous, endometrioid, clear cell or mucinous ovarian cancer and normal ovarian tissue ([Table I](#tI-ol-0-0-10818){ref-type="table"}).

### Prognostic value of TKT in ovarian cancer

The prognostic value of transketolase family genes was assessed. Survival information for the three transketolase genes was obtained from the Kaplan-Meier plotter. The prognostic value of TKT mRNA expression in ovarian cancer was evaluated; the Affymetrix identifier (ID) was 205168_at TKT. PFS curves were plotted for all patients with ovarian cancer (N=1,435; [Fig. 2A](#f2-ol-0-0-10818){ref-type="fig"}), patients with serous cancer (N=1,104; [Fig. 2B](#f2-ol-0-0-10818){ref-type="fig"}) and endometrioid cancer (N=51; [Fig. 2C](#f2-ol-0-0-10818){ref-type="fig"}). Increased expression levels of TKT mRNA were identified to be associated with poorer PFS in all patients with ovarian cancer (HR, 1.25; 95% CI, 1.10--1.42; P=0.0007). High TKT expression was also associated with poor PFS in serous ovarian cancer (HR, 1.27; 95% CI, 1.10--1.47; P=0.0010). However, TKT mRNA expression levels were not associated with PFS in patients with endometrioid cancer. The OS between the high and low-TKT expression groups in all ovarian cancer and serous ovarian cancer cases was not significantly different ([Fig. 3A and B](#f3-ol-0-0-10818){ref-type="fig"}). TKT mRNA expression was not associated with OS in patients with endometrioid cancer ([Fig. 3C](#f3-ol-0-0-10818){ref-type="fig"}).

### Prognostic value of TKTL1 in ovarian cancer

The prognostic value of TKTL1 mRNA expression in ovarian cancer was evaluated; the Affymetrix ID was 216370_s\_at TKTL1. No differences were observed in PFS between the high and low-TKTL1 expression groups in all patients with ovarian cancer ([Fig. 4A](#f4-ol-0-0-10818){ref-type="fig"}). However, stratified analyses demonstrated that high expression of TKTL1 was associated with poor PFS in patients with serous ovarian cancer (HR, 1.27; 95% CI, 1.08--1.50; P=0.0036; [Fig. 4B](#f4-ol-0-0-10818){ref-type="fig"}), as well as in patients with endometrioid ovarian cancer (HR, 4.33; 95% CI, 0.99--18.88; P=0.0340; [Fig. 4C](#f4-ol-0-0-10818){ref-type="fig"}). TKTL1 mRNA expression levels were not associated with OS in all patients with ovarian cancer ([Fig. 5A](#f5-ol-0-0-10818){ref-type="fig"}), nor in patients with serous ovarian cancer ([Fig. 5B](#f5-ol-0-0-10818){ref-type="fig"}) or endometrioid ovarian cancer ([Fig. 5C](#f5-ol-0-0-10818){ref-type="fig"}).

### Prognostic value of TKTL2 in ovarian cancer

The prognostic value of TKTL2 mRNA expression in ovarian cancer was evaluated; the Affymetrix ID was 223829_at TKTL2. High TKTL2 mRNA expression indicated unfavorable PFS for all patients with ovarian cancer (HR, 1.49; 95% CI, 1.19--1.85; P=0.0004; [Fig. 6A](#f6-ol-0-0-10818){ref-type="fig"}) and patients with serous ovarian cancer (HR, 1.44; 95% CI, 1.13--1.84; P=0.0031; [Fig. 6B](#f6-ol-0-0-10818){ref-type="fig"}). However, TKTL2 mRNA expression levels were not associated with PFS in patients with endometrioid ovarian cancer ([Fig. 6C](#f6-ol-0-0-10818){ref-type="fig"}). High expression of TKTL2 was associated with OS in all patients with ovarian cancer (HR, 1.38; 95% CI, 1.07--1.76; P=0.0110; [Fig. 7A](#f7-ol-0-0-10818){ref-type="fig"}). TKTL2 exhibited no association with OS in patients with serous ovarian cancer ([Fig. 7B](#f7-ol-0-0-10818){ref-type="fig"}) or endometrioid ovarian cancer ([Fig. 7C](#f7-ol-0-0-10818){ref-type="fig"}).

### Prognostic value of transketolase family genes in different subtypes of ovarian cancer

The association between individual transketolase gene mRNA expression levels and clinicopathological features of patients with ovarian cancer was analyzed. Only samples with the relevance clinical information were included. The association with pathological clinical stage ([Table II](#tII-ol-0-0-10818){ref-type="table"}), grade ([Table III](#tIII-ol-0-0-10818){ref-type="table"}), chemotherapy treatment ([Table IV](#tIV-ol-0-0-10818){ref-type="table"}) and TP53 mutation status ([Table V](#tV-ol-0-0-10818){ref-type="table"}) of patients with ovarian cancer was determined. As presented in [Table II](#tII-ol-0-0-10818){ref-type="table"}, the three transketolase genes were associated with poor PFS in patients with stage III/IV ovarian cancer, but not stage I/II ovarian cancer. The individual transketolase genes were associated with poor PFS in patients with grade I/II and grade III ovarian cancer ([Table III](#tIII-ol-0-0-10818){ref-type="table"}). TKT and TKTL2 were associated with unfavorable PFS in patients with ovarian cancer treated with platinum chemotherapy ([Table IV](#tIV-ol-0-0-10818){ref-type="table"}). In addition, high levels of TKTL1 and TKTL2 were associated with poor PFS in patients with ovarian cancer treated with taxol chemotherapy ([Table IV](#tIV-ol-0-0-10818){ref-type="table"}). The association between transketolase family gene expression levels and PFS of ovarian cancer patients was also evaluated based on the TP53 mutation status; the individual transketolase genes were only significantly associated with poor PFS in patients with TP53-mutated ovarian cancer, but not in those with TP53 wild-type ovarian cancer.

### Validation of prognostic values of transketolase family genes in ovarian cancer

For the verification of the prognostic roles of transketolase family genes, the GSE9891 dataset was analyzed by log-rank test ([Fig. 8](#f8-ol-0-0-10818){ref-type="fig"}). Similar results to the Kaplan-Meier plotter analysis were observed: In all patients with ovarian cancer, high expression levels of TKT and TKTL2 were associated with poor PFS, whereas TKTL1 was not associated with PFS.

Discussion
==========

Transketolases, which are key enzymes of the non-oxidative branch of the pentose phosphate pathway, are associated with the tumorigenesis and development of a variety of tumors ([@b10-ol-0-0-10818]). The aim of the current study was to investigate the expression levels and prognostic values of transketolase genes in ovarian cancer.

TKT is not only involved in cancer development and progression, but also contributes to patient survival. For example, TKT has been reported to be upregulated in hepatocellular carcinoma ([@b5-ol-0-0-10818]). In addition, high TKT expression levels indicate poor survival in hepatocellular carcinoma and esophageal cancer ([@b5-ol-0-0-10818],[@b16-ol-0-0-10818]). A number of previous studies have indicated carcinogenic roles for TKT in breast cancer and gynecological tumors. In breast cancer, Tseng *et al* ([@b30-ol-0-0-10818]) demonstrated that TKT expression levels were upregulated in breast cancer compared with those in normal tissue, and were higher in metastatic lymphoid tissue compared with those in the primary site. Further analysis of the association between TKT expression and clinical parameters identified that TKT expression was associated with breast cancer stage and grade, patient age, and tumor size and type; in addition, patients with high TKT expression exhibited a worse outcome compared with that observed in the low-TKT expression group ([@b30-ol-0-0-10818]). A study by Yang *et al* ([@b31-ol-0-0-10818]) revealed that TKT was highly expressed in 81.1% of cervical cancer samples and was significantly upregulated in cervical cancer compared with its expression in normal cervical tissue. Chen *et al* ([@b32-ol-0-0-10818]) compared serum peptide profiles among healthy control subjects and patients with cervical cancer prior and subsequent to surgery. The results demonstrated that TKT expression levels were higher in patients with cervical cancer prior to surgery compared with those in healthy subjects and patients following surgery. In addition, TKT is expressed in ascites fluid from patients with ovarian cancer, but not from individuals with benign lesions ([@b21-ol-0-0-10818]). Yi *et al* ([@b33-ol-0-0-10818]) identified TKT in exosomes derived from two late-stage ovarian cancer cell lines and suggested that TKT may serve a dominant role in exosome-mediated carcinogenicity and cancer progression. Depletion of TKT by TKT siRNA inhibited proliferation in ovarian cancer cells *in vitro* ([@b22-ol-0-0-10818]). Oxythiamine, a transketolase inhibitor, also decreased tumor cell proliferation in ovarian cancer cell lines and primary serous ovarian cancer cells ([@b22-ol-0-0-10818]). Only one study is available concerning the prognostic values of TKT in ovarian cancer, which reported that patients with high nuclear TKT expression in peritoneal metastases exhibited shorter OS time compared with that of patients with low TKT protein levels ([@b22-ol-0-0-10818]). However, no correlation was identified between PFS and TKT expression in either primary cancer or peritoneal metastases ([@b22-ol-0-0-10818]). Thus, whether or not TKT mRNA has a prognostic role in patients with ovarian cancer remains to be determined. In the present study, a significant upregulation of TKT expression was observed in ovarian cancer compared with that in normal ovarian tissue. In addition, high TKT mRNA expression was associated with poor PFS in all patients with ovarian cancer, as well as in patients with serous-type ovarian cancer. Although the OS between the high and low-TKT expression groups in all ovarian cancer and serous ovarian cancer samples was not significantly different, the P-value was \<0.1.

The mechanism underlying the carcinogenic roles of TKT in tumors has been investigated in a number of studies. A recent study has reported that TKT interacts with SH2 domain-containing 5 and activates STAT3 phosphorylation, thus promoting the proliferation of liver cancer cells ([@b34-ol-0-0-10818]). This result suggested that STAT3 may be involved in the regulation of liver cancer cell proliferation by TKT. Lin *et al* ([@b35-ol-0-0-10818]) demonstrated that the knockdown of TKT prevents vascular endothelial growth factor secretion and inhibits cell proliferation in lung cancer. To the best of our knowledge, no conclusive results are available on the mechanism of TKT in ovarian cancer, which needs further investigation.

Previous studies have demonstrated that TKTL1 serves crucial roles in cancer prognosis. High expression levels of TKTL1 have been reported to be a significant indicator of poor outcome in colorectal ([@b36-ol-0-0-10818]) and gastric ([@b18-ol-0-0-10818]) cancer, esophageal squamous cell carcinoma ([@b37-ol-0-0-10818]), and locally advanced rectal ([@b38-ol-0-0-10818]) and non-small cell lung ([@b17-ol-0-0-10818]) cancer. In ovarian cancer, TKTL1 expression was observed in 81% of granulosa cell tumors of the ovary, but not in normal ovarian tissue ([@b39-ol-0-0-10818]). Krockenberger *et al* ([@b40-ol-0-0-10818]) also demonstrated that the expression of TKTL1 is significantly higher in tumor tissues of serous papillary ovarian adenocarcinomas compared with that in borderline tumors or normal tissues. In addition, increased expression of TKTL1 was associated with higher Federation International of Gynecology and Obstetrics stage, initial ascites and higher histopathological grade in serous papillary ovarian carcinoma ([@b40-ol-0-0-10818]). These results indicated that TKTL1 may be an oncogene in ovarian carcinogenesis and development. However, to the best of our knowledge, no studies on the prognostic significance of TKTL1 in ovarian cancer are currently available. In the present study, upregulation of TKTL1 expression was demonstrated in all ovarian cancer cases, especially in serous ovarian cancer. In addition, high TKTL1 mRNA expression levels were significantly associated with poor PFS in patients with serous and endometrioid ovarian cancer. However, when the histological types of ovarian cancer were not distinguished, TKTL1 exhibited no effects on PFS in all patients with ovarian cancer due to the different cut-off values in different histological types. The cut-off values used for serous and endometrioid ovarian cancer in the present study were 10 and 24, respectively, which meant that patients with serous and endometrioid ovarian cancer were split differently to separate the high and low-expression groups. According to this divisional standard, patients with serous ovarian cancer with transcription level \>10 comprised the high expression group, whereas patients with serous ovarian cancer with transcription level \<10 comprised the low expression group. In endometrioid ovarian cancer, patients whose expression value is \>24 should be classified in the high expression group, whereas patients whose expression value is \<24 should be classified in the low expression group. However, if this study used the same cut-off, such as 15, to separate the high and low groups, ignoring the histological types of ovarian cancer, serous ovarian cancer patients with actually high expression would be mistakenly defined as low group, and endometrioid ovarian cancer patients with actually low expression would be mistakenly classified as high expression, thereby affecting the results of analysis. Therefore, the histology of ovarian cancer should be considered when assessing the prognostic roles of TKTL1 in ovarian cancer.

Studies on the function of TKTL2 in malignancies are limited. Chen *et al* ([@b41-ol-0-0-10818]) compared TKTL2 expression between uterine cervix cancer cells and normal human endocervical epithelial cells, and no significant differences between the two types of cell lines were observed. A similar result was observed in nasopharyngeal carcinoma ([@b42-ol-0-0-10818]). To the best of our knowledge, no studies on TKTL2 in ovarian cancer are currently available. In the present study, TKTL2 expression levels were compared between serous, endometrioid, clear cell or mucinous ovarian cancer tissues and normal ovarian tissues; however, no differences were observed. By contrast, high TKTL2 mRNA expression was significantly associated with poor PFS and OS in all patients with ovarian cancer. The negative result of the relative expression of TKTL2 in ovarian cancer may be due to the limited sample size, as the Lu dataset, which was used to compare the differential expression of TKTL2 between tumor and normal tissue, only included 5 normal ovarian tissue samples. Differential expression of TKTL2 between ovarian cancer and normal ovarian tissue requires further study.

The prognostic value of the transketolase family genes in ovarian cancer with different clinical stages was further investigated. The three transketolase genes were associated with poor PFS in patients with stage III/IV ovarian cancer, but exhibited no effects on PFS among patients with stage I/II ovarian cancer. These results suggested that the transketolase family genes may be a negative prognostic indicator for late-stage ovarian cancer.

Platinum and taxol are the two most frequently used chemotherapeutic drugs for treating ovarian cancer ([@b43-ol-0-0-10818]). However, a number of patients ultimately progress to recurrent, chemotherapy-resistant tumors, and the majority of these patients succumb to the disease within one year ([@b44-ol-0-0-10818]). There is a great need to identify prognostic markers to predict the outcome of patients with ovarian cancer treated with platinum and paclitaxel. The results of the present study demonstrated that the transketolase family genes were associated with chemotherapy sensitivity in ovarian cancer. Transketolase family genes served different roles in chemotherapy sensitivity. The results revealed that enhanced TKT expression was associated with unfavorable PFS in patients with ovarian cancer treated with platinum, whereas high TKTL1 expression was associated with poor PFS in patients treated with taxol. TKTL2 was associated with poor outcomes in patients treated with platinum plus taxol. These results were consistent with those from previous studies. Taoka *et al* ([@b45-ol-0-0-10818]) compared differential protein expression profiles between platinum-naïve and platinum-resistant bladder cancer cell lines to identify the candidate molecules associated with platinum resistance, and revealed that the expression of TKT was increased by 1.5-fold in platinum-resistant bladder cancer compared with that in platinum-naïve cells. Yang *et al* ([@b31-ol-0-0-10818]) also demonstrated that silencing of TKT significantly reduced cell viability and increased apoptosis in the presence of platinum via glutathione depletion and reactive oxygen species generation in cervical cancer. In addition, overexpression of TKT increased resistance to platinum chemotherapy by increasing cell viability and decreasing apoptosis in cervical cancer *in vitro* ([@b31-ol-0-0-10818]). A study on the role of TKTL1 in taxol sensitivity revealed that the inhibition of TKTL1 significantly decreased the proliferation rate and the IC~50~ of taxol in ovarian cancer ([@b46-ol-0-0-10818]). Mechanistically, following TKTL1 knockdown, NADPH levels were reduced and NADP^+^ levels were increased compared with the levels in the control group, which led to taxol sensitivity in ovarian cancer ([@b46-ol-0-0-10818]).

The TP53 gene, located on chromosome 17p13, encodes the tumor-suppressor protein p53 ([@b47-ol-0-0-10818]). TP53 serves an important role in the regulation of the cell cycle, DNA repair and cell death through apoptosis ([@b48-ol-0-0-10818]). Mutation or loss of function of the TP53 gene is a frequent and important genetic alteration in the development of ovarian cancer ([@b49-ol-0-0-10818]). Harami-Papp *et al* ([@b50-ol-0-0-10818]) compared gene expression between TP53-mutated and wild-type tissue samples from patients with breast cancer and revealed that transketolase was upregulated in TP53-mutated breast cancer compared with its expression in TP53 wild-type breast cancer. In the present study, the prognostic roles of individual transketolase genes in patients with ovarian cancer with different TP53 mutation status were examined; the three transketolase family genes were associated with poor PFS in patients with TP53-mutated, but not with TP53 wild-type, ovarian cancer. Therefore, the transketolase family may have an effect on the prognosis of TP53-mutated ovarian cancer.

A lack of experimental data was the main limitation of the present study. To strengthen the conclusions, cell and animal models with transketolase gene knockdown and overexpression may be constructed, which would verify the tumorigenic functions of transketolase genes in ovarian cancer. Future studies may also collect clinical information and perform immunohistochemistry on clinical cervical cancer samples to subsequently validate the prognostic roles of transketolase genes.

In summary, the present study identified elevated TKT and TKTL1 expression in ovarian cancer compared with that in normal ovarian tissue. High mRNA expression of the above three transketolase genes was demonstrated to be associated with poor PFS in patients with serous ovarian cancer, especially those at an advanced clinical stage. TKTL2 was also significantly associated with poor OS in all patients with ovarian cancer. In addition, transketolase family genes served a role in predicting PFS in patients with ovarian cancer treated with platinum and/or taxol, as well as in patients with TP53-mutated ovarian cancer. These results suggest that transketolase genes have a prognostic value in ovarian cancer. This may facilitate better prognostic stratification and may be useful for the detailed understanding of the complexity and heterogeneity implicated in the molecular biology of ovarian cancer.
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###### 

Comparison of the expression profile of transketolase family genes in normal ovarian tissue vs. various types of ovarian cancer.

                         Tissues, n         
  ------- -------------- ------------ ----- ---------------------------------------------------------------------
  TKT     Serous         8            586   0.409
          Endometrioid   9            46    \<0.001^[a](#tfn1-ol-0-0-10818){ref-type="table-fn"}^ (upregulated)
          Clear cell     9            15    0.007^[a](#tfn1-ol-0-0-10818){ref-type="table-fn"}^ (upregulated)
          Mucinous       9            22    0.001^[a](#tfn1-ol-0-0-10818){ref-type="table-fn"}^ (upregulated)
  TKTL1   Serous         8            586   \<0.001^[a](#tfn1-ol-0-0-10818){ref-type="table-fn"}^ (upregulated)
          Endometrioid   9            46    0.164
          Clear cell     9            15    0.463
          Mucinous       9            22    0.324
  TKTL2   Serous         5            20    0.311
          Endometrioid   5            9     0.113
          Clear cell     5            7     0.066
          Mucinous       5            9     0.147

P\<0.05. TKT, transketolase; TKTL1, TKT-like 1; TKTL2, TKT-like 2.

###### 

Association of transketolase family genes with progression-free survival in patients with different clinical stages of ovarian cancer.

  Transketolase family gene   Clinical stage   Patients, n   HR (95% CI)         P-value
  --------------------------- ---------------- ------------- ------------------- ------------------------------------------------------
  TKT                         I+II             163           0.75 (0.42--1.34)   0.3300
                              III+IV           1,081         1.24 (1.08--1.43)   0.0025^[a](#tfn2-ol-0-0-10818){ref-type="table-fn"}^
  TKTL1                       I+II             163           1.40 (0.76--2.59)   0.2800
                              III+IV           1,081         1.32 (1.12--1.56)   0.0008^[a](#tfn2-ol-0-0-10818){ref-type="table-fn"}^
  TKTL2                       I+II             115           2.06 (0.84--5.08)   0.1100
                              III+IV           494           1.36 (1.08--1.70)   0.0079^[a](#tfn2-ol-0-0-10818){ref-type="table-fn"}^

P\<0.05. TKT, transketolase; TKTL1, TKT-like 1; TKTL2, TKT-like 2; HR, hazard ratio; CI, confidence interval.

###### 

Association of transketolase family genes with progression-free survival in patients with different pathological grades of ovarian cancer.

  Transketolase family gene   Pathological grade   Patients, n   HR (95% CI)         P-value
  --------------------------- -------------------- ------------- ------------------- ------------------------------------------------------
  TKT                         I+II                 293           1.46 (1.09--1.96)   0.0120^[a](#tfn3-ol-0-0-10818){ref-type="table-fn"}^
                              III                  837           1.21 (1.03--1.43)   0.0220^[a](#tfn3-ol-0-0-10818){ref-type="table-fn"}^
  TKTL1                       I+II                 293           1.41 (1.04--1.91)   0.0250^[a](#tfn3-ol-0-0-10818){ref-type="table-fn"}^
                              III                  837           1.37 (1.12--1.67)   0.0020^[a](#tfn3-ol-0-0-10818){ref-type="table-fn"}^
  TKTL2                       I+II                 189           1.53 (1.03--2.28)   0.0350^[a](#tfn3-ol-0-0-10818){ref-type="table-fn"}^
                              III                  315           1.51 (1.18--1.95)   0.0011^[a](#tfn3-ol-0-0-10818){ref-type="table-fn"}^

P\<0.05. TKT, transketolase; TKTL1, TKT-like 1; TKTL2, TKT-like 2; HR, hazard ratio; CI, confidence interval.

###### 

Association of transketolase family genes with progression-free survival in patients with ovarian cancer who received chemotherapy.

  Transketolase family gene   Chemotherapy       Patients, n   HR (95% CI)         P-value
  --------------------------- ------------------ ------------- ------------------- ------------------------------------------------------
  TKT                         Platinum           1,259         1.19 (1.05--1.36)   0.0078^[a](#tfn4-ol-0-0-10818){ref-type="table-fn"}^
                              Taxol              715           1.16 (0.95--1.40)   0.1400
                              Taxol + platinum   698           1.14 (0.94--1.39)   0.1900
  TKTL1                       Platinum           1,259         0.91 (0.80--1.04)   0.1500
                              Taxol              715           1.23 (1.03--1.48)   0.0250^[a](#tfn4-ol-0-0-10818){ref-type="table-fn"}^
                              Taxol + platinum   698           1.24 (1.03--1.50)   0.0240^[a](#tfn4-ol-0-0-10818){ref-type="table-fn"}^
  TKTL2                       Platinum           502           1.31 (1.08--1.59)   0.0063^[a](#tfn4-ol-0-0-10818){ref-type="table-fn"}^
                              Taxol              381           1.44 (1.13--1.84)   0.0031^[a](#tfn4-ol-0-0-10818){ref-type="table-fn"}^
                              Taxol + platinum   380           1.44 (1.13--1.83)   0.0034^[a](#tfn4-ol-0-0-10818){ref-type="table-fn"}^

P\<0.05. TKT, transketolase; TKTL1, TKT-like 1; TKTL2, TKT-like 2; HR, hazard ratio; CI, confidence interval.

###### 

Association of transketolase family genes with progression-free survival in patients with ovarian cancer with different TP53 mutation status.

  Transketolase family gene   TP53 mutation   Patients, n   HR (95% CI)         P-value
  --------------------------- --------------- ------------- ------------------- ------------------------------------------------------
  TKT                         No              84            0.59 (0.32--1.07)   0.0780
                              Yes             483           1.53 (1.22--1.92)   0.0002^[a](#tfn5-ol-0-0-10818){ref-type="table-fn"}^
  TKTL1                       No              84            1.59 (0.91--2.79)   0.1000
                              Yes             483           1.37 (1.07--1.75)   0.0130^[a](#tfn5-ol-0-0-10818){ref-type="table-fn"}^
  TKTL2                       No              19            2.03 (0.64--6.38)   0.2200
                              Yes             124           1.88 (1.24--2.86)   0.0027^[a](#tfn5-ol-0-0-10818){ref-type="table-fn"}^

P\<0.05. TP53, tumor protein p53; HR, hazard ratio; CI, confidence interval; TKT, transketolase; TKTL1, TKT-like 1; TKTL2, TKT-like 2.
